| 51 |
25016642 | Actively targeted cetuximab conjugated gamma-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells. | 2014 Aug |
5 |
| 52 |
25057173 | EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer. | 2014 Oct |
1 |
| 53 |
25059320 | Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer. | 2014 Oct |
1 |
| 54 |
25219817 | Pharmacotherapy targeting the EGFR oncogene in NSCLC. | 2014 Nov |
1 |
| 55 |
25474307 | Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism. | 2014 |
2 |
| 56 |
22608542 | Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines. | 2013 Nov |
1 |
| 57 |
23192362 | Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity. | 2013 May |
1 |
| 58 |
23493804 | Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation. | 2013 |
3 |
| 59 |
23590835 | Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity. | 2013 Apr 16 |
1 |
| 60 |
23910066 | Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status. | 2013 Nov |
3 |
| 61 |
24155892 | Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer. | 2013 |
2 |
| 62 |
21947696 | Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin. | 2012 Mar |
1 |
| 63 |
22429575 | [Sequence-dependent effect of docetaxel with gefitinib on the proliferation and apoptosis of lung adenocarcinoma cell H1975]. | 2012 Mar |
1 |
| 64 |
22977195 | Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). | 2012 Nov 1 |
1 |
| 65 |
22994780 | Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line. | 2012 |
1 |
| 66 |
20665703 | ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells. | 2011 Feb |
2 |
| 67 |
20705357 | First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. | 2011 Apr |
2 |
| 68 |
20864569 | Empowering induction therapy for locally advanced head and neck cancer. | 2011 Apr |
1 |
| 69 |
21035484 | Targeting the cancer initiating cell: the Achilles' heel of cancer. | 2011 |
1 |
| 70 |
21197560 | miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. | 2011 Apr |
1 |
| 71 |
21569641 | [Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1]. | 2011 May |
1 |
| 72 |
21681119 | Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer. | 2011 Oct |
1 |
| 73 |
21796416 | Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation. | 2011 Sep |
1 |
| 74 |
22848267 | Differential efficacy of docetaxel according to non-small cell lung cancer histology and the therapeutic effect of epidermal growth factor receptor tyrosine kinase inhibitors. | 2011 Nov |
1 |
| 75 |
20022809 | Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. | 2010 Feb |
1 |
| 76 |
20028750 | Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. | 2010 Jan 1 |
2 |
| 77 |
20038723 | Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. | 2010 Feb 10 |
3 |
| 78 |
20179163 | Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. | 2010 Mar |
3 |
| 79 |
20513026 | XRP6258-induced gene expression patterns in head and neck cancer carcinoma. | 2010 Jun |
1 |
| 80 |
20878103 | Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS. | 2010 Nov |
3 |
| 81 |
23074402 | Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. | 2010 |
1 |
| 82 |
18758819 | In vitro effect of radiation, antibody to epidermal growth factor receptor and Docetaxel in human head and neck squamous carcinoma cells with mutant P53 and over-expressed EGFR. | 2009 Feb |
1 |
| 83 |
19229369 | The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement. | 2009 Jan |
1 |
| 84 |
19352302 | Chemotherapy-induced tumor gene expression changes in human breast cancers. | 2009 Mar |
2 |
| 85 |
19399750 | Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer. | 2009 Oct |
3 |
| 86 |
19530244 | Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. | 2009 Nov 15 |
2 |
| 87 |
19884861 | EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. | 2009 Dec |
2 |
| 88 |
18025070 | Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. | 2008 Mar |
5 |
| 89 |
18418213 | Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma. | 2008 Jun |
3 |
| 90 |
18799900 | [Advances in chemotherapy for lung cancer]. | 2008 Sep |
1 |
| 91 |
17363490 | Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. | 2007 Mar |
1 |
| 92 |
17505004 | Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck. | 2007 May 15 |
2 |
| 93 |
17638896 | Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. | 2007 Jul 15 |
1 |
| 94 |
16984384 | Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. | 2006 Oct |
3 |
| 95 |
15897421 | An in vivo evaluation of docetaxel delivered intratumorally in head and neck squamous cell carcinoma. | 2005 May |
1 |
| 96 |
15985306 | Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib. | 2005 Oct |
1 |
| 97 |
15234052 | C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. | 2004 Jul 15 |
2 |
| 98 |
15332713 | Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro. | 2004 Aug |
2 |
| 99 |
14657531 | Activation of tyrosine kinases in cancer. | 2003 |
1 |
| 100 |
12473607 | Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. | 2002 Dec |
2 |